Key result
The ISTH-BAT scoring system was unable to effectively discriminate patients with platelet function defects from those without the condition (AUC 0.620; 95% CI 0.415-0.825).
Why the study?
Few studies have evaluated the utility of the ISTH-BAT structured bleeding assessment tool in diagnosing patients with platelet function defects.
Does the ISTH-BAT scoring system accurately diagnose platelet function defects in patients suspected of having them?
Cross-Sectional (n=61)
Does the ISTH-BAT scoring system accurately diagnose platelet function defects in patients suspected of having them?
Effect estimate: AUC 0.620 (95% CI 0.415-0.825)
The ISTH-BAT scoring system has good discriminatory power in diagnosing patients with PFDs from healthy controls but is ineffective in differentiating them from those with suspected but unconfirmed PFDs.
ISTH-BAT may help triage suspected PFD cases for testing; leaves open its diagnostic thresholds and routine use pending validation.
The ISTH-BAT is a structured bleeding assessment tool to record and help diagnose patients with possible bleeding disorders. However, a few studies evaluated the utility of ISTH-BAT in diagnosing patients with platelet function defects (PFDs). In this study, we evaluated the diagnostic utility of ISTH-BAT in predicting PFDs among patients suspected of PFDs. Forty patients suspected of PFDs and 21 normal healthy controls were evaluated by the ISTH-BAT scoring system, light transmission aggregometry (LTA), ATP-releasing assays (lumi-aggregometry), and expression of CD62P for diagnosis of PFDs. Among 40 patients suspected of PFDs, 10 were diagnosed as PFDs using lumiaggregometry and CD62P. The ISTH-BAT score in patients suspected of PFDs [(6, interquartile range (IQR) 1-8] and patients with PFDs was significantly higher than the control group (0; IQR 0-0) ( P < 0.001). Receiver operating characteristic curves indicate that ISTH-BAT is not able to discriminate patients with PFDs from those without PFDs (areas under the curve of 0.620 (95% confidence interval 0.415-0.825). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the ISTH-BAT in predicting the presence of PFDs, respectively, were 40, 73.3, 33.3, and 78.6% in the cut-off ISTH-BAT at least 4 in adult men, at least 6 in adult women, and at least 3 in children (age < 18). The ISTH-BAT scoring system has good discriminatory power in diagnosing patients with PFDs from healthy controls but is ineffective in differentiating them from those without PFDs.
No takes yet. Share an insight, caveat, or question.
Shahbazi et al. (2023) conducted a cross-sectional in Platelet function defects (n=61). ISTH-BAT scoring system vs. Healthy controls and patients without platelet function defects was evaluated on Discrimination of patients with platelet function defects from those without the condition (AUC 0.620, 95% CI 0.415-0.825). The ISTH-BAT scoring system was unable to effectively discriminate patients with platelet function defects from those without the condition (AUC 0.620; 95% CI 0.415-0.825).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: